Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Younger Age and Antibody Induction Increase the Risk for Infection in Pediatric Renal Transplantation: A NAPRTCS Report

Go back to Resources

Younger Age and Antibody Induction Increase the Risk for Infection in Pediatric Renal Transplantation: A NAPRTCS Report

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity

Go back to Resources

Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Second Annual Analysis of the Collaborative Islet Transplant Registry

Go back to Resources

Second Annual Analysis of the Collaborative Islet Transplant Registry

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals

Go back to Resources

Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Pegaptanib for Advanced Von Hippel-Lindau Disease of the Retina

Go back to Resources

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Pegaptanib for Advanced Von Hippel-Lindau Disease of the Retina

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Effects of Long-term Zinc Supplementation on Plasma Thiol Metabolites and Redox Status in Patients With Age-Related Macular Degeneration

Go back to Resources

Effects of Long-term Zinc Supplementation on Plasma Thiol Metabolites and Redox Status in Patients With Age-Related Macular Degeneration

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Effect of the Orally Administered PKC b Inhibitor, Ruboxistaurin, on Visual Acuity in the PKC-DRS2 Study

Go back to Resources

Effect of the Orally Administered PKC b Inhibitor, Ruboxistaurin, on Visual Acuity in the PKC-DRS2 Study

Authors:

Location:

Go back to Resources

Effect of the orally administered PKC b Inhibitor, Ruboxistaurin, on sustained moderate visual loss in the PKC-DRS2 Study

Go back to Resources

Effect of the orally administered PKC b Inhibitor, Ruboxistaurin, on sustained moderate visual loss in the PKC-DRS2 Study

Authors:

Location:

Go back to Resources

Effect of the oral protein kinase C b Inhibitor, Ruboxistaurin, on visual acuity in the PKC-DRS2 Study

Go back to Resources

Effect of the oral protein kinase C b Inhibitor, Ruboxistaurin, on visual acuity in the PKC-DRS2 Study

Authors:

Location:

Go back to Resources

Effect of Ruboxistaurin on reversibility of vision loss in nonproliferative diabetic retinopathy patients

Go back to Resources

Effect of Ruboxistaurin on reversibility of vision loss in nonproliferative diabetic retinopathy patients

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 166
  • Page 167
  • Page 168
  • Page 169
  • Current page 170
  • Page 171
  • Page 172
  • Page 173
  • Page 174
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification